Clinical Oncology News | Lenalidomide Indication Expanded To Include MCL Clinical Oncology News The expanded indication is based on the results of MCL-001, a Phase II, multicenter, open-label, single-arm trial that included 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline or mitoxantrone ... |
